Summit Therapeutics Inc vs SSR Mining Inc. Common Stock — how do they compare? Summit Therapeutics Inc trades at $17.28 (market cap $13.71B), while SSR Mining Inc. Common Stock trades at $34.26 (market cap $6.83B). The key difference: Summit Therapeutics Inc is far larger — about 2× SSR Mining Inc. Common Stock's market cap, and SSR Mining Inc. Common Stock pays a 0.09% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and SSR Mining Inc. Common Stock for 0 Days on average.
| SMMT | SSRM | |
|---|---|---|
Market Cap | $13.71B | $6.83B |
Volume | 6,173,057 | 1,863,519 |
Sector | Health | Basic Materials |
52-Week High | $26.38 | $39.21 |
52-Week Low | $12.43 | $19.48 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $13.04B | $5.00B |
Dividend Yield | — | 0.09% |
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.33. The stock has surged recently following a $2 billion strategic equity investment from AstraZeneca and expanded clinical collaborations. However, the company remains pre-revenue with significant losses, reflected in a negative ROE of -192.5% and negative EBITDA of -$1.08 billion for 2025.
The outlook is driven by clinical progress for ivonescimab, but high execution risk and cash burn necessitate close monitoring. Investment opportunity hinges on successful drug development, while key risks include trial outcomes and funding needs. The stock offers high-risk, high-reward potential based on pipeline milestones.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →SSR Mining operates precious-metals mines in the United States, Canada, and Argentina. It produces gold doré and concentrates containing copper, silver, lead, and zinc.
Read more on SSRM →